Table 6.
Prediction of Heart Failure Event- 2060 subjects (28 events).
| Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age | 1.06 (1.02, 1.10) | 0.006 | |||
| Body mass index | 1.06 (1.01, 1.10) | 0.011 | |||
| Medical History | |||||
| Diabetes | 4.8 (2.2, 10.6) | <0.001 | |||
| Hypertension | 2.3 (1.1, 4.8) | 0.033 | |||
| Dyslipidemia | 3.0 (1.3, 6.7) | 0.009 | |||
| Coronary artery disease | 8.6 (2.6, 28.5) | <0.001 | |||
| Prior heart failure | 15.4 (4.6, 51.0) | <0.001 | |||
| Chronic kidney disease | 3.4 (0.5, 25.3) | 0.226 | |||
| Chronic obstructive pulmonary disease | 3.5 (1.1, 11.7) | 0.039 | |||
| Smoking | 1.3 (0.8, 1.9) | 0.26 | |||
| Beta blocker | 5.1 (2.1, 12.6) | <0.001 | 2.4 (0.9, 6.1) | 0.07 | |
| ACE-inhibitor | 2.5 (1.0, 6.2) | 0.045 | |||
| Angiotensin receptor blocker | 1.6 (0.6, 4.6) | 0.378 | |||
| Aldosterone antagonist | -- (--, --) | -- | |||
| Statin | 2.6 (1.1, 6.2) | 0.026 | |||
| Breast Cancer Characteristics | |||||
| Cancer stage | 0 or 1 | Reference | |||
| 2 | 0.5 (0.2, 1.4) | 0.185 | |||
| 3 | 1.1 (0.4, 3.1) | 0.85 | |||
| Receptor status | Hormone positive, HER2 negative | Reference | |||
| HER2 positive | 0.7 (0.3, 1.7) | 0.499 | |||
| Triple negative | 1.4 (0.5, 4.1) | 0.566 | |||
| Cancer Therapy | |||||
| Use of anthracycline therapy | 1.0 (0.5, 2.1) | 0.948 | |||
| Anthracycline dose | 1.0 (1.0, 1.0) | 0.412 | |||
| Number of trastuzumab cycles | 0.98 (0.94, 1.03) | 0.532 | |||
| Left chest irradiation | 1.0 (0.4, 2.6) | 0.972 | |||
| Cardiac Imaging | |||||
| Baseline imaging (Echo vs. MUGA) | 0.9 (0.4, 1.9) | 0.787 | |||
| Baseline LVEF, per 1% increase | 1.04 (0.98, 1.10) | 0.222 | |||
| Occurrence of CTRCD | 3.6 (1.6, 7.9) | 0.002 | |||
| Follow-up Cardiac Imaging | All MUGA | Reference | |||
| All Echo | 1.3 (0.4, 4.7) | 0.657 | |||
| Mixed modality | 1.4 (0.3, 7.7) | 0.694 | |||
| None | 1.0 (0.3, 3.0) | 0.983 | |||
| HFA-ICOS risk | Low | Reference | |||
| Moderate | 3.4 (1.2, 9.7) | 0.025 | 3.2 (1.1, 9.2) | 0.032 | |
| High or Very high | 19.4 (6.8, 55.0) | <0.001 | 16.0 (5.5, 47.1) | <0.001 | |
All results are expressed as hazard ratio (95% confidence intervals) or frequency (percentage).
For this secondary outcome, the above parameters with univariable P<0.2 underwent stepwise forward selection. The final model includes moderate or “high or very high” HFA-ICOS risk. Other parameters are no longer significant in the multivariable model.
HR, hazard ratio; CI, confidence intervals; MUGA, multi-gated acquisition; ACE, angiotensin converting enzyme; HER2, human epidermal growth factor receptor-2; CTRCD, cancer therapy related cardiac dysfunction; HFA-ICOS, European Society of Cardiology Heart Failure Association - International Cardio-Oncology Society.